Subsidy Information and Financing Scheme MSHLSelinexor Tablet 20 mg 1) Selinexor in combination with bortezomib and dexamethasone for the treatment of patients with re... See all × MSHLSelinexor Tablet 20 mg 1) Selinexor in combination with bortezomib and dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma who have received at least one prior therapy. 2) In combination with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti‐CD38 monoclonal antibody.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Tablet 20 mg National Cancer Centre